Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment-Reference-Cited by-同舟云学术

Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment

Published:2019-10 Issue:S2 Volume:24 Page:
ISSN:1085-9489
Container-title:Journal of the Peripheral Nervous System
language:en
Short-container-title:J Peripher Nerv Syst

Author:

Velasco Roser¹²^ORCID,Alberti Paola³⁴,Bruna Jordi¹²,Psimaras Dimitri⁵⁶⁷^ORCID,Argyriou Andreas A.⁸

Affiliation:

1. Unit of Neuro‐OncologyHospital Universitari de Bellvitge‐Institut Català D'Oncologia L'Hospitalet, IDIBELL Barcelona Spain

2. Department of Cell Biology, Physiology and Immunology, Institute of NeurosciencesUniversitat Autònoma de Barcelona, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Bellaterra Spain

3. NeuroMI (Milan Center for Neuroscience) Milan Italy

4. School of Medicine and SurgeryUniversity of Milano‐Bicocca Monza Italy

5. AP‐HP, Hôpitaux Universitaires La Pitié Salpêtrière ‐ Charles FoixService de Neurologie Mazarin Paris France

6. Inserm U 1127, CNRS UMR 7225Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM Paris France

7. OncoNeuroTox Group, Center for Patients with Neurological Complications of Oncologic TreatmentsHôpitaux Universitaires Pitié‐Salpetrière‐Charles Foix et Hôpital Percy Paris France

8. Department of Neurology“Saint Andrew's” State General Hospital of Patras Patras Greece

Publisher

Wiley

Subject

Neurology (clinical),General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jns.12338

Reference104 articles.

1. Single‐agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy;Richardson PG;J Clin Oncol,2009

2. Proteasome inhibitors in cancer therapy;Manasanch EE;Nat Rev Clin Oncol,2017

3. Neurological monitoring reduces the incidence of bortezomib‐induced peripheral neuropathy in multiple myeloma patients;Velasco R;J Peripher Nerv Syst,2010

4. Evaluation of Bortezomib‐Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib‐Based Induction;Lakshman A;Clin Lymphoma Myeloma Leuk,2017

5. Chemotherapy‐induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice;Beijers AJ;Support Care Cancer,2016

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma;American Journal of Hematology;2024-06-10

2. Bortezomib-induced peripheral neuropathy: Clinical features, molecular basis, and therapeutic approach;Critical Reviews in Oncology/Hematology;2024-05

3. The nociceptive activity of peripheral sensory neurons is modulated by the neuronal membrane proteasome;Cell Reports;2024-04

4. Spatial sequestration of activated-caspase 3 in aggresomes mediates resistance of neuroblastoma cell to bortezomib treatment;Scientific Reports;2024-02-14

5. A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients;Oncology Research;2024